Adipsin Is Associated with Multiple Sclerosis: A Follow-Up Study of Adipokines

Table 1

Demographic and clinical characteristics of patients with different MS phenotypes.

	RRMS	SPMS	PPMS	CIS
Gender F/M^a	24/10	10/5	9/7	13/2
Age (years)^b	37.6 ± 9.2; (20–51)	49.3 ± 10.0; (32–63)	58.1 ± 8.5; (40–70)	35.6 ± 7.9; (24–51)
BMI (kg/m^2)^b	24.9 ± 4.0; (19.7–35.4)	26.2 ± 5.0; (15.8–33.3)	24.6 ± 3.4; (19.8–31.5)	25.3 ± 3.2; (21.6–31.2)
Disease duration from first symptoms (years)^b	8.2 ± 7.2; (0.7–29.6)	19.8 ± 7.8; (6.3–34.3)	18.9 ± 9.6; (2.4–43.0)	3.0 ± 2.5; (0.5–8.9)
Disease duration from diagnosis (years)^b	4.2 ± 4.1; (0.0–13.7)	12.9 ± 9.0; (2.2–32.4)	13.1 ± 8.4; (1.5–27.2)	NA
EDSS at baseline^b	1.4 ± 1.5; (0.0–6.0)	5.2 ± 1.6; (2.5–7.5)	4.7 ± 2.2; (1.0–7.0)	0.1 ± 0.3; (0.0–1.0)
EDSS at end of the follow-up^b	1.5 ± 1.6; (0.0–6.0)	5.5 ± 1.6; (2.5–8.0)	4.8 ± 2.1; (1.5–7.0)	0.1 ± 0.4; (0.0–1.0)
EDSS worsening during follow-up^c	7 (21%)	6 (40%)	4 (25%)	1 (7%)
Prestudy disease activity^b,d	1.2 ± 1.4; (0–5)	0.2 ± 0.6; (0–2)	0.0 ± 0.0; (0-0)	0.7 ± 0.6; (0–2)
Number of relapses over the follow-up^b	0.6 ± 1.1; (0–5)	0.4 ± 0.7; (0–2)	0.0 ± 0.0; (0-0)	0.1 ± 0.3; (0-1)
Treatment (NT/IFN/CO/MX)^a	12/18/3/1	15/0/0/0	16/0/0/0	15/0/0/0

RRMS: relapsing-remitting MS, SPMS: secondary progressive MS, PPMS: primary progressive MS, CIS: clinically isolated syndrome, BMI: body mass index, EDSS: expanded disability status scale, NT: no treatment, IFN: interferon, CO: copaxone, MX: mitoxantrone, and NA: not applicable.
Number of patients.
Mean ± SD (range).
Number of patients (percent).
Number of relapses in the 2 years before baseline.